Dan Zang
Impact in
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Oncology top 10%
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Gut microbiota and health 5
- Ubiquitin and proteasome pathways 4
-
- Cancer-related molecular mechanisms research 4
- MicroRNA in disease regulation 4
- Cancer, Lipids, and Metabolism 3
- Co-authors
- Jun Chen (6 shared papers)Chong Zhao (10 shared papers)Xiaoying Lan (9 shared papers)Xuejun Wang (9 shared papers)Xin Chen (9 shared papers)Hongbiao Huang (9 shared papers)Xianping Shi (9 shared papers)Shiqian Chen (3 shared papers)
- Journals
- Oncotarget (4 papers)Frontiers in Immunology (3 papers)Frontiers in Oncology (2 papers)Toxicology Letters (2 papers)Scientific Reports (2 papers)
- Partner nations
- ChinaUnited StatesBelgium
In The Last Decade
Dan Zang
37 papers receiving 839 citations
Dan Zang's Hit Papers
Peers
Comparison fields: 5 of 83
- Cancer Research 140
- Oncology 211
- Molecular Biology 467
- Hematology 57
- Biological Psychiatry 9
Countries citing papers authored by Dan Zang
This map shows the geographic impact of Dan Zang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Zang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Zang more than expected).
Fields of papers citing papers by Dan Zang
This network shows the impact of papers produced by Dan Zang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Zang. The network helps show where Dan Zang may publish in the future.
Co-authors
The 25 scholars most cited alongside Dan Zang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 89 | |
| 2 | Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review) Hit paper breakdown → | 2024 | 73 |
| 3 | 2014 | 71 | |
| 4 | 2015 | 59 | |
| 5 | 2016 | 52 | |
| 6 | 2015 | 50 | |
| 7 | 2016 | 36 | |
| 8 | 2020 | 35 | |
| 9 | 2012 | 33 | |
| 10 | 2017 | 31 | |
| 11 | 2024 | 29 | |
| 12 | 2016 | 26 | |
| 13 | 2024 | 23 | |
| 14 | 2015 | 23 | |
| 15 | 2016 | 21 | |
| 16 | LPPR4 promotes peritoneal metastasis via Sp1/integrin α/FAK signaling in gastric cancer. | 2020 | 20 |
| 17 | 2017 | 19 | |
| 18 | 2017 | 18 | |
| 19 | 2018 | 17 | |
| 20 | 2024 | 16 |
About Dan Zang
Dan Zang is a scholar working on Molecular Biology, Cancer Research, Oncology, Pulmonary and Respiratory Medicine and Hematology, having authored 41 papers that have together received 852 indexed citations. Recurring topics across this work include Gut microbiota and health (5 papers), Ubiquitin and proteasome pathways (4 papers), Cancer-related molecular mechanisms research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), MicroRNA in disease regulation (4 papers), Chronic Myeloid Leukemia Treatments (3 papers), Peptidase Inhibition and Analysis (3 papers) and Cancer, Lipids, and Metabolism (3 papers). The work is most often cited by research in Cancer Research (140 citations), Oncology (211 citations), Molecular Biology (467 citations), Hematology (57 citations) and Biological Psychiatry (9 citations). Dan Zang has collaborated with scholars based in China, United States and Belgium. Frequent co-authors include Jun Chen, Chong Zhao, Xiaoying Lan, Xuejun Wang, Xin Chen, Hongbiao Huang, Xianping Shi, Shiqian Chen, Ningning Liu and Jinbao Liu. Their work appears in journals such as Oncotarget, Frontiers in Immunology, Frontiers in Oncology, Toxicology Letters and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.